CCXI News and Press, ChemoCentryx Inc. From 08/04/22

Amgen ( NASDAQ: AMGN ) has agreed to buy ChemoCentryx ( CCXI ), a drug developer focused on autoimmune disorders, for $3.7B in cash, the companies announced on Thursday in an emailed statement. ChemoCentryx ( CCXI ) shares jumped ~109% after the news. Amgen ( ...

Amgen ( NASDAQ: AMGN ) has agreed to buy ChemoCentryx ( CCXI ) a drug developer focused on autoimmune disorders for $3.7B in cash, the companies announced on Thursday in an emailed statement. Amgen ( AMGN ) shares are currently trading marginally lower while ChemoC...

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH PR Newswire Acquisition Includes TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephr...

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call an...

SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constitut...

Today, we revisit a biopharma concern called ChemoCentryx for the first time since late in 2021. The company is in the initial rollout of its primary product TAVNEOS, which is approved for one indication and in development for three other diseases. ChemoCentryx has a solid balance...

-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 20...

SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS ® (avacopan), an orally administered selective complement 5a recep...

-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the composition of its Boar...

The following slide deck was published by ChemoCentryx, Inc. in conjunction with this event. For further details see: ChemoCentryx (CCXI) Presents At H.C. Wainwright Global Investment Conference - Slideshow